PA8469301A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimientos para la preparacion de acidos hidroxamicos.
|
PA8469601A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Procedimiento para alquilar sulfonamidas impedidas estericamente
|
GT199900044A
(es)
*
|
1998-04-10 |
2000-09-14 |
|
Procedimientos para preparar haluros de fenoxifenilsulfonilo.
|
DE69917124T2
(de)
*
|
1998-04-10 |
2005-05-12 |
Pfizer Products Inc., Groton |
Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
|
WO2000058278A1
(en)
*
|
1999-03-26 |
2000-10-05 |
Shionogi & Co., Ltd. |
β-AMINO ACID DERIVATIVES
|
WO2000058280A1
(fr)
*
|
1999-03-26 |
2000-10-05 |
Shionogi & Co., Ltd. |
Derives de sulfonamide carbocyclique
|
DE60003863T2
(de)
*
|
1999-03-31 |
2004-04-22 |
Pfizer Products Inc., Groton |
Dioxocyclopentylhydroxamsäure
|
MXPA01013324A
(es)
|
1999-08-18 |
2002-07-02 |
Warner Lambert Co |
Compuestos de acido hidroxamico utiles como inhibidores de metaloproteinasa de matriz.
|
IL138686A0
(en)
*
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
AU2002231368C1
(en)
|
2001-01-05 |
2018-08-16 |
Amgen Fremont Inc. |
Antibodies to insulin-like growth factor I receptor
|
PT1373262E
(pt)
*
|
2001-03-14 |
2010-07-26 |
Novartis Ag |
DERIVADOS áCIDO ACéTICO SUBSTITUDO COM AZACICLOALQUILO PARA UTILIZAÃO COMO INIBIDORES DE MMP
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
JP4313678B2
(ja)
*
|
2001-12-27 |
2009-08-12 |
大日本住友製薬株式会社 |
ヒドロキサム酸誘導体およびそれを有効成分とするmmp阻害剤
|
PT1585743E
(pt)
|
2002-12-19 |
2007-07-12 |
Pfizer |
Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
GB0326546D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Amersham Plc |
Inhibitor imaging agents
|
CA2546353A1
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
US20080095704A1
(en)
*
|
2004-07-02 |
2008-04-24 |
Alan Cuthbertson |
Imaging Agents with Improved Pharmacokinetic Profiles
|
BRPI0513915A
(pt)
|
2004-08-26 |
2008-05-20 |
Pfizer |
compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
CA2649122C
(en)
|
2006-04-18 |
2015-06-30 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
KR20090111847A
(ko)
|
2007-01-19 |
2009-10-27 |
아디아 바이오사이언스즈 인크. |
Mek 억제제
|
UA97834C2
(ru)
|
2007-04-18 |
2012-03-26 |
Пфайзер Продактс Инк. |
Производные сульфониламида для лечения анормального роста клеток
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
EP2222675B1
(en)
|
2007-12-19 |
2013-09-11 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
AU2008340247B2
(en)
|
2007-12-21 |
2012-11-15 |
Genentech, Inc. |
Azaindolizines and methods of use
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
ES2586032T3
(es)
|
2008-03-28 |
2016-10-11 |
Hale Biopharma Ventures, Llc |
Administración de composiciones de benzodiazepinas
|
US8895546B2
(en)
|
2009-03-27 |
2014-11-25 |
Hale Biopharma Ventures, Llc |
Administration of benzodiazepine compositions
|
CA3014224C
(en)
|
2009-02-05 |
2022-05-24 |
Immunogen, Inc. |
Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2459191A1
(en)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Mtor inhibitor and angiogenesis inhibitor combination therapy
|
EP2488507B1
(en)
|
2009-10-13 |
2014-12-17 |
Allostem Therapeutics LLC |
Novel mek inhibitors, useful in the treatment of diseases
|
PL2496567T3
(pl)
|
2009-11-05 |
2018-01-31 |
Rhizen Pharmaceuticals S A |
Nowe benzopiranowe modulatory kinazy
|
TW201141536A
(en)
*
|
2009-12-21 |
2011-12-01 |
Colgate Palmolive Co |
Oral care compositions and methods
|
CA2789629A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc. |
Cd20 antibodies and uses thereof
|
EP3150610B1
(en)
|
2010-02-12 |
2019-07-31 |
Pfizer Inc |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2519826A2
(en)
|
2010-03-03 |
2012-11-07 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦***-匹兹堡大学 |
内质蛋白的抗体及其用途
|
UA115767C2
(uk)
|
2011-01-10 |
2017-12-26 |
Інфініті Фармасьютікалз, Інк. |
Способи отримання ізохінолінонів і тверді форми ізохінолінонів
|
SG191955A1
(en)
|
2011-02-15 |
2013-08-30 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
WO2013126617A1
(en)
|
2012-02-22 |
2013-08-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Bouvardin derivatives and therapeutic uses thereof
|
US9452215B2
(en)
|
2012-02-22 |
2016-09-27 |
The Regents Of The University Of Colorado |
Bourvadin derivatives and therapeutic uses thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CA2875989A1
(en)
|
2012-06-08 |
2013-12-12 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
HUE045227T2
(hu)
|
2012-08-31 |
2019-12-30 |
Sutro Biopharma Inc |
Azido csoportot tartalmazó módosított aminosavak
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
CN108997225A
(zh)
|
2013-03-14 |
2018-12-14 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
BR112017021869A2
(pt)
|
2015-04-10 |
2018-12-11 |
Araxes Pharma Llc |
compostos quinazolina substituídos e métodos de uso dos mesmos
|
MX2017013275A
(es)
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
EP3611506B1
(en)
|
2015-04-20 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
JP6510075B2
(ja)
|
2015-05-18 |
2019-05-08 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
バイオアベイラビリティが高いアルボシジブプロドラッグ
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
EP3331510A4
(en)
|
2015-08-03 |
2019-04-03 |
Tolero Pharmaceuticals, Inc. |
COMBINATORIAL THERAPIES FOR THE TREATMENT OF CANCER
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤をスクリーニングするための方法
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
MX2018006781A
(es)
|
2015-12-03 |
2018-11-09 |
Agios Pharmaceuticals Inc |
Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
US11708413B2
(en)
|
2016-01-27 |
2023-07-25 |
Sutro Biopharma, Inc. |
Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
CA3024556A1
(en)
|
2016-05-12 |
2017-11-16 |
The Regents Of The University Of Michigan |
Ash1l inhibitors and methods of treatment therewith
|
US11118233B2
(en)
|
2016-05-18 |
2021-09-14 |
The University Of Chicago |
BTK mutation and ibrutinib resistance
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
DK3558955T3
(da)
|
2016-12-22 |
2021-10-25 |
Amgen Inc |
Benzisothiazol-, isothiazolo[3,4-b]pyridin-, quinazolin-, phthalazin-, pyrido[2,3-d]pyridazin- og pyrido[2,3-d]pyrimidinderivater som kras-g12c-inhibitorer til behandling af lunge-, pankreas- eller kolorektalcancer
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
WO2018137705A1
(en)
|
2017-01-26 |
2018-08-02 |
Zai Lab (Shanghai) Co., Ltd. |
Cd47 antigen binding unit and uses thereof
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
WO2018218070A2
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
US11542248B2
(en)
|
2017-06-08 |
2023-01-03 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
CN116003405A
(zh)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
SG11202002310UA
(en)
|
2017-09-18 |
2020-04-29 |
Sutro Biopharma Inc |
Anti- folate receptor alpha antibody conjugates and their uses
|
TW201920170A
(zh)
|
2017-09-20 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
經取代之menin-mll 抑制劑及使用方法
|
US10632209B2
(en)
|
2017-11-10 |
2020-04-28 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US11013741B1
(en)
|
2018-04-05 |
2021-05-25 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL kinase inhibitors and use of the same
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP4155293A1
(en)
|
2018-06-07 |
2023-03-29 |
The Regents of The University of Michigan |
Prc1 inhibitors and methods of treatment therewith
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019391097A1
(en)
|
2018-12-04 |
2021-05-20 |
Sumitomo Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
ES2953821T3
(es)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
Inhibidores de KIF18A
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
IL283639B1
(en)
|
2018-12-20 |
2024-02-01 |
Amgen Inc |
KIF18A inhibitors
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
JP2022519923A
(ja)
|
2019-03-22 |
2022-03-25 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pkm2モジュレーターを含む組成物およびそれを使用する処置の方法
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CN114302880A
(zh)
|
2019-08-02 |
2022-04-08 |
美国安进公司 |
Kif18a抑制剂
|
EP4007638A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
MX2022005053A
(es)
|
2019-10-28 |
2022-05-18 |
Merck Sharp & Dohme Llc |
Inhibidores de peque?as moleculas de mutante g12c de kras.
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
BR112022008565A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
KR20220124768A
(ko)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
Shp2 억제제 투여 및 암 치료방법
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
AU2021293228A1
(en)
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
KR20230031926A
(ko)
|
2020-07-15 |
2023-03-07 |
다이호야쿠힌고교 가부시키가이샤 |
종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
|
KR20230081726A
(ko)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
AR124449A1
(es)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
Inhibidores de sos1 y usos de los mismos
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
US20220396589A1
(en)
|
2021-05-05 |
2022-12-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
EP4347041A1
(en)
|
2021-05-28 |
2024-04-10 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|